Search company, investor...
My Intelligent Machines company logo

My Intelligent Machines

mims.ai

Founded Year

2016

Stage

Series A | Alive

Total Raised

$6.67M

Last Raised

$3.99M | 2 yrs ago

About My Intelligent Machines

My Intelligent Machines is a platform as a service helping biologists analyze genomic data using AI. The platform finds the appropriate algorithms to analyze the user's data and generates text on its methods of analysis.

Headquarters Location

51 Sherbrooke street West Office 101

Montreal, Quebec, H2X 1X2,

Canada

438-375-1269

My Intelligent Machines's Product Videos

ESPs containing My Intelligent Machines

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Healthcare Providers Tech

Companies in this market reduce the cost of clinical trials by simulating patient cohorts and testing drugs on simulated versions of living entities. Synthetic data vendors use real patient records to create “fake” data that is non-identifiable but still holds predictive power that is useful for drug discovery, clinical trials, and treatment decisions.

My Intelligent Machines named as Outperformer among 8 other companies, including GNS Healthcare, Twin Health, and Q Bio.

Compete with My Intelligent Machines?

Ensure that your company and products are accurately represented on our platform.

My Intelligent Machines's Products & Differentiators

    SaaS platform

    Stand alone platform including access to 16000 patients cohort, scientific literature insights and the 3 solutions mentioned above: PopSeg, Target, Biomark in oncology and immuno-oncology.

Research containing My Intelligent Machines

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned My Intelligent Machines in 1 CB Insights research brief, most recently on Oct 26, 2022.

Expert Collections containing My Intelligent Machines

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

My Intelligent Machines is included in 8 Expert Collections, including Digital Health.

D

Digital Health

21,907 items

Startups recreating how healthcare is delivered

C

Clinical Trials Tech

366 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

A

Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

C

Clinical Trials Tech Market Map

108 items

This CB Insights Tech Market Map highlights 100+ clinical trials tech companies that are addressing 8 distinct technology priorities that pharmaceutical companies and CROs face.

B

Biopharma Tech

326 items

Latest My Intelligent Machines News

My Intelligent Machines Launches Powerful New Software for Drug Development in Oncology

Jun 5, 2022

Share My Intelligent Machines (MIMs)—a leader in harnessing the power of systems biology, bioinformatics, and artificial intelligence launched a product poised to change the way companies prepare for clinical trials in oncology. Using a sophisticated systems biology and machine learning platform built specifically for them, life scientists are now able to predict good responders to new therapies with more than two-times higher performance than other available methodologies. Further, they are able to do a month’s work in a single day, delivering results at a tenth of the cost of bioinformatics and data science consulting services. MIMs’ software solution in oncology uses expression data from 16,000 patients across more than 200 cancer types and is able to provide key insights on drug mechanisms of action and drug synergies in individual patient contexts. “As a biologist, I always dreamed of being more autonomous in my research involving next generation sequencing; of having the ability to explore my ideas and insights without the cost, time, and reliance on others to help me process and analyze my own data,” says Sarah Jenna , MIMs’ co-founder and CEO. “With MIMs, life scientists can now independently harness the power of systems biology, artificial intelligence, and their own deep human knowledge and experience in cancer biology to push the boundaries of innovation and drug discovery.” MIMs’ oncology-research product delivers scientific insights to support strategic decisions on indication prioritization at preclinical stage. It enables researchers to increase the success rate of Phase II and III clinical trials; explore new potent combined therapies; and accelerate early high-value biomarkers to accelerate companion test development. Related Posts MIMs’ platform integrates the company’s MIMsight Knowledge Base—which combines billions of data points and other information extracted from scientific literature, public databases, multi-omic and clinical patient data—and MIMs’ proprietary GI2 algorithm, which infers genetic interactions within patient tumors and immune systems. The platform creates vivid human cartographies of individual patients, which deliver previously unimagined levels of precise insight used to classify patients into subgroups, identify their molecular and clinical characteristics, predict their response to new therapies, and identify powerful therapeutic targets and biomarkers. Jenna continues, laughing. “Six years ago, when we explained to people what we were building our platform to do, they called it science fiction! Today, these same people are buying annual licenses.” My Intelligent Machines will be in Chicago this week, at the American Society of Clinical Oncology (ASCO) Meeting and invites people to stop by Booth IH20 to learn more about this exciting new approach. To celebrate the product launch, and being back at ASCO in-person, MIMs is offering special promotional pricing, with a 30-percent discount on its Lite and Plus SaaS platform packages. The company also encourages those interested in a free 30-day trial to contact them directly.

My Intelligent Machines Frequently Asked Questions (FAQ)

  • When was My Intelligent Machines founded?

    My Intelligent Machines was founded in 2016.

  • Where is My Intelligent Machines's headquarters?

    My Intelligent Machines's headquarters is located at 51 Sherbrooke street West, Montreal.

  • What is My Intelligent Machines's latest funding round?

    My Intelligent Machines's latest funding round is Series A.

  • How much did My Intelligent Machines raise?

    My Intelligent Machines raised a total of $6.67M.

  • Who are the investors of My Intelligent Machines?

    Investors of My Intelligent Machines include Anges Quebec, Medteq, AQC Capital, StandUp Ventures, Desjardins Capital and 6 more.

  • Who are My Intelligent Machines's competitors?

    Competitors of My Intelligent Machines include Seven Bridges, Turbine, Owkin, AnaBios, METiS Therapeutics, BenevolentAI, VeriSIM Life, Unlearn, Syntegra, Replica Analytics and 27 more.

  • What products does My Intelligent Machines offer?

    My Intelligent Machines's products include SaaS platform and 4 more.

  • Who are My Intelligent Machines's customers?

    Customers of My Intelligent Machines include Biopharmaceutical: PharmaEngine, Inc and Research Institute of the McGill University Health Center.

Compare My Intelligent Machines to Competitors

GNS Healthcare Logo
GNS Healthcare

GNS is a health tech company using Causal AI and simulation technology to discover and validate drug targets, simulate clinical trials. GNS’ patented AI uncovers new insights from multi-omics and real-world data to discover and prioritize biological targets, and more efficient clinical trials with patients who are likely to respond to therapies. The Gemini Digital Twin models across oncology, auto-immune diseases, and neurology enable the simulation of disease progression and drug response at the individual patient level to simulate clinical trials in diverse patient cohorts. GNS Healthcare was founded in 2000 and is based in Somerville, Massachusetts.

I
InSilico Trials

InSilicoTrials.com is a web-based platform, which provides a user-friendly computational modeling and simulation environment where many integrated easy-to-use in silico tools are readily available. The platform targets primarily users from the medical devices and pharmaceutical sectors. The company was founded in 2017 and is based in Trieste, Italy.

D
Delta 4

Delta 4 is a drug discovery and development company combining in-silico drug discovery and big data analysis with expertise in molecular biology and clinical development to a powerful proprietary drug discovery platform. This platform generates promising drug candidates annotated with biological and medical information, resulting in a fast-track to establish a clinical proof of concept. The Company focuses on the discovery of indications for approved drugs (drug repositioning). In its first therapeutic area, focal segmental glomerulosclerosis (FSGS), a devastating renal disease with high and urgent medical need, Delta 4 has identified and pre-clinically validated promising drug candidates that are currently prepared for clinical proof-of-concept. In 2020, the Company applied its drug discovery platform to additional indications. As a result, Delta 4 has readied a potential COVID-19 therapy for Phase 1 development and filed four patent applications for compounds in two indications.

O
Oncocross

Oncocross develops drugs to treat orphan diseases and intractable diseases including cancers. Using its ONCO AI platform, the company has developed products including sarcopenia drugs, anti-metastasis drugs, liver cirrhosis drugs, and irritable bowel syndrome (IBS) drugs.

P
PharmCADD

PharmCADD develops Pharmulator, a computer-aided drug discovery and development platform that utilizes computational science methodologies, advanced machine learning technologies, and molecular dynamics.

Acellera Logo
Acellera

Acellera is a computational drug discovery company that develops ACEMD, a solution for building, simulating, and analyzing molecular systems, and PlayMolecule, a platform that offers molecular dynamics and machine learning applications for drug discovery with a specific focus on drug design.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.